{"product_id":"gilead-business-model-canvas","title":"Gilead Sciences Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead Sciences: Compact Business Model Canvas for Strategic Growth Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Gilead Sciences’s business model — this concise Business Model Canvas maps value propositions, key partners, revenue streams, and scalability levers to reveal how Gilead sustains growth and competitive advantage; ideal for investors, consultants, and entrepreneurs seeking actionable, ready-to-use insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Oncology Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead partners with biotechs like Arcus Biosciences to co-develop TIGIT inhibitors and next-gen cancer immunotherapies, sharing late-stage trial costs—Arcus deal milestones exceeded $1.2B by 2025 and cut Gilead’s trial capex exposure by ~35% in 2024–25.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGalapagos NV Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe long-term research partnership with Galapagos NV gives Gilead exclusive access to Galapagos’s small-molecule inflammation discovery platform, strengthening Gilead’s immunology pipeline in rheumatoid arthritis and inflammatory bowel disease; as of 2025 the deal has supported \u0026gt;€1.1bn in shared R\u0026amp;D investment and potential milestone payments, includes shared R\u0026amp;D facilities, and grants Gilead options for commercialization rights outside Europe, accelerating late-stage candidate development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health and NGO Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead partners with WHO and the Medicines Patent Pool to license generics for HIV and hepatitis drugs, enabling generic manufacturing in 100+ low- and middle-income countries; in 2024 these programs supported treatment access for an estimated 12 million people globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead uses third-party contract manufacturing organizations (CMOs) to produce active pharmaceutical ingredients and finished forms, letting it scale quickly—Gilead reported ~$27.6B revenue in 2024 and relies on CMOs to meet global demand spikes without heavy capital spend.\u003c\/p\u003e\n\u003cp\u003eThis flexibility is critical for complex biologics and cell therapies, where CMOs provide specialized handling and allow rapid launch scaling during health crises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduce capex, faster ramp\u003c\/li\u003e\n\u003cli\u003eSupport biologics\/cell therapy needs\u003c\/li\u003e\n\u003cli\u003eEnable surge capacity in pandemics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead funds and partners with leading universities and clinical research orgs to run early discovery and pivotal phase trials, giving access to top scientific talent and diverse patient cohorts.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 these academic ties remain Gilead’s primary long-term innovation source in virology and cell therapy, supporting ~35% of R\u0026amp;D pipeline projects and \u0026gt;$420m in collaborative funding in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~35% of pipeline projects from academic collaborations\u003c\/li\u003e\n\u003cli\u003e$420m collaborative funding in 2024\u003c\/li\u003e\n\u003cli\u003eDiverse patient access for global pivotal trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead partnerships slash trial costs, unlock €1.1B R\u0026amp;D, 12M patients, $27.6B support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead’s key partnerships cut trial capex ~35% (Arcus), unlocked \u0026gt;€1.1bn shared R\u0026amp;D (Galapagos), enabled generic access for ~12M patients (WHO\/MPP 2024), and relied on CMOs to support $27.6B 2024 revenue and surge biologics capacity; academic ties funded ~$420M in 2024 and underpinned ~35% of pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024–25 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eArcus\u003c\/td\u003e\n\u003ctd\u003e$1.2B milestones; -35% trial capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalapagos\u003c\/td\u003e\n\u003ctd\u003e€1.1B shared R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWHO\/MPP\u003c\/td\u003e\n\u003ctd\u003e12M patients reached (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eSupport $27.6B revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e$420M funding; ~35% pipeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Gilead Sciences outlining customer segments, value propositions, channels, key partners, activities, resources, cost structure, and revenue streams, reflecting its biopharma R\u0026amp;D-driven, commercial-stage strategy focused on antivirals, oncology, and cell therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Gilead Sciences’ business model with editable cells, condensing R\u0026amp;D, pipeline, commercial strategy, and partnerships into a one-page snapshot that saves hours of structuring and is perfect for boardroom review or team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead’s core R\u0026amp;D centers on discovering and clinically testing novel molecules, from target ID to managing multi‑phase global trials; R\u0026amp;D spend was $6.2B in 2024 (≈18% of revenue) and remains focused in 2025 on expanding Trodelvy indications and advancing long‑acting HIV regimens with multiple Phase 2\/3 studies underway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead spends heavily on regulatory affairs to secure approvals from the FDA, EMA and others, managing clinical dossiers and post‑market safety; in 2024 the company reported R\u0026amp;D plus SG\u0026amp;A of about $9.6B, much of which supports regulatory and compliance functions. Navigating shifting laws and pharmacovigilance demands—e.g., routine safety reporting and electronic submissions—remains a continuous, resource‑intensive activity across dozens of jurisdictions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead runs advanced manufacturing for small molecules and biologics, including CAR-T via Kite Pharma, operating 20+ global sites and investing $1.5B in capacity through 2024 to meet demand; strict QC (batch release, sterility, potency) supports 99.9% regulatory compliance and reduces recall risk across its supply chain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead runs specialized sales teams, medical-conference programs, and digital physician portals to drive uptake of its therapies; in 2024 Gilead reported $27.5B in product sales, with HIV-related revenues ~20% of total.\u003c\/p\u003e\n\u003cp\u003eIn 2025 the commercialization push centers on long-acting injectables for HIV, aiming to convert oral patients—Gilead projects mid-single-digit annual share gains in key markets within 3 years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized sales forces\u003c\/li\u003e\n\u003cli\u003eMedical conferences \u0026amp; KOL engagement\u003c\/li\u003e\n\u003cli\u003eDigital physician portals\u003c\/li\u003e\n\u003cli\u003e2024 product sales $27.5B\u003c\/li\u003e\n\u003cli\u003eHIV ~20% of revenue\u003c\/li\u003e\n\u003cli\u003e2025 focus: long-acting injectable rollout\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead protects innovations via a targeted patent strategy, managing ~6,400 global family patents (2024) to recoup R\u0026amp;D spend—R\u0026amp;D was $5.6B in 2024—while defending against generics and seeking extensions for blockbusters like Biktarvy and Trodelvy.\u003c\/p\u003e\n\u003cp\u003eThat IP management preserves high product gross margins (Biktarvy \u0026gt;80% gross margin historically), funding ongoing R\u0026amp;D and new pipelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~6,400 global patent families (2024)\u003c\/li\u003e\n\u003cli\u003e$5.6B R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eBiktarvy gross margin \u0026gt;80%\u003c\/li\u003e\n\u003cli\u003eActive litigation and patent term extensions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead 2024: $6.2B R\u0026amp;D, $27.5B Sales, 20% HIV, $1.5B Manufacturing, 6.4K Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead’s key activities: global R\u0026amp;D and multi‑phase trials ($6.2B R\u0026amp;D, 18% revs in 2024), regulatory submissions and pharmacovigilance (R\u0026amp;D+SG\u0026amp;A ~$9.6B), biologic\/small‑molecule manufacturing (20+ sites, $1.5B capacity spend through 2024), sales \u0026amp; medical engagement (2024 sales $27.5B; HIV ~20%) and IP management (~6,400 patent families, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$6.2B (18% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003e$27.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV share\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing spend\u003c\/td\u003e\n\u003ctd\u003e$1.5B capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent families\u003c\/td\u003e\n\u003ctd\u003e~6,400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the exact Gilead Sciences Business Model Canvas you will receive after purchase—not a mockup or sample—and it contains real, editable content laid out for immediate use.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you’ll download this same professional document in full, formatted and ready for editing, presenting, or sharing with no hidden pages or altered content.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749311787385,"sku":"gilead-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/gilead-business-model-canvas.png?v=1772214028","url":"https:\/\/matrixbcg.com\/products\/gilead-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}